# Prestige Biopharma

Source: https://onco.cc/companies/prestige-biopharma/  
OnCo record `prestige-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Prestige Biopharma is a Singapore-based antibody company, listed in Korea, that makes biosimilars and is developing PBP1510, a first-in-class antibody against the pancreatic cancer protein PAUF.

## Summary

Prestige Biopharma develops biosimilars, including trastuzumab (Tuznue) and bevacizumab candidates, and novel antibodies. PBP1510 (ulenistamab) neutralises pancreatic adenocarcinoma up-regulated factor (PAUF), a secreted protein that drives tumour growth and immune evasion; it has orphan designations in the United States and Europe and is in a phase 1/2a trial with gemcitabine in advanced pancreatic cancer. The company also develops PBP1710 against CTHRC1.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Prestige BioPharma Limited; KRX:950210
- Tags: drug-maker
- HQ: Singapore
- Type: biotech
- Website: https://www.prestigebiopharma.com/
- Ticker: KRX:950210

## Sources

- Official website: https://www.prestigebiopharma.com/

## Connected records

- drugs: [PBP1510](https://onco.cc/drugs/pbp1510/)

---
JSON: https://onco.cc/api/v1/entities/prestige-biopharma.json